The human NTG model of migraine in drug discovery and development.
Lanfranco PellesiPublished in: Expert opinion on drug discovery (2023)
The NTG model represents a potential de-risking strategy to test novel hypotheses for antimigraine mechanisms in humans. Considering previous studies conducted with effective and ineffective antimigraine therapies, the sensitivity of the model was 71% while the specificity was 100%. The probability that following an analgesic effect, that compound would truly be efficacious in individuals with migraine was 100%. Following a negative result, the probability that such compound would truly be ineffective in patients with individuals was 33%. A clinical trial testing the analgesic properties of novel compounds after a sublingual and/or intravenous NTG challenge in migraine patients may support a subsequent phase 2 trial for the treatment of migraine.
Keyphrases
- drug discovery
- clinical trial
- endothelial cells
- ejection fraction
- newly diagnosed
- randomized controlled trial
- prognostic factors
- high dose
- anti inflammatory
- risk assessment
- low dose
- study protocol
- chronic kidney disease
- patient reported outcomes
- double blind
- climate change
- smoking cessation
- induced pluripotent stem cells
- replacement therapy
- allergic rhinitis
- patient reported
- phase iii